The cost of pretomanid, a crucial tuberculosis drug, has fallen by 25% to under $1 per day as of April. The price reduction follows the launch of a new formulation by Lupin, a Mumbai-based manufacturer.
Lupin is one of five companies licensed by the non-profit TB Alliance to produce pretomanid, fostering competition to drive prices down and ensure market access.
To speak to us about this, we are joined on the line by Dr. Mel Spigelman, President and CEO of TB Alliance.

South Africa's foreign policy under scrutiny
09:12

DRC, Rwanda agree to a series of coordinated steps to de-escalate tensions
09:20

Congo-Brazzaville waits for Sunday's election results
10:42